IL283839A - Peptides that target the transferrin receptor - Google Patents

Peptides that target the transferrin receptor

Info

Publication number
IL283839A
IL283839A IL283839A IL28383921A IL283839A IL 283839 A IL283839 A IL 283839A IL 283839 A IL283839 A IL 283839A IL 28383921 A IL28383921 A IL 28383921A IL 283839 A IL283839 A IL 283839A
Authority
IL
Israel
Prior art keywords
transferrin receptor
targeting peptides
receptor targeting
peptides
transferrin
Prior art date
Application number
IL283839A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IL283839A publication Critical patent/IL283839A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
IL283839A 2018-12-14 2021-06-09 Peptides that target the transferrin receptor IL283839A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779885P 2018-12-14 2018-12-14
US201962836520P 2019-04-19 2019-04-19
PCT/US2019/066376 WO2020124032A1 (en) 2018-12-14 2019-12-13 Transferrin receptor targeting peptides

Publications (1)

Publication Number Publication Date
IL283839A true IL283839A (en) 2021-07-29

Family

ID=71077078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283839A IL283839A (en) 2018-12-14 2021-06-09 Peptides that target the transferrin receptor

Country Status (8)

Country Link
US (1) US20220048961A1 (cg-RX-API-DMAC7.html)
EP (1) EP3893913B1 (cg-RX-API-DMAC7.html)
JP (2) JP7664158B2 (cg-RX-API-DMAC7.html)
CN (1) CN113329758A (cg-RX-API-DMAC7.html)
AU (1) AU2019398467A1 (cg-RX-API-DMAC7.html)
CA (1) CA3120466A1 (cg-RX-API-DMAC7.html)
IL (1) IL283839A (cg-RX-API-DMAC7.html)
WO (1) WO2020124032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP7231745B2 (ja) 2020-06-22 2023-03-01 中国科学院昆明▲動▼物研究所 抗SARS-CoV-2薬の調製における干渉ポリペプチドの応用
CN111647048B (zh) * 2020-06-22 2021-04-02 中国科学院昆明动物研究所 干扰多肽在制备抗SARS-CoV-2药物中的应用
JP2022014707A (ja) * 2020-07-07 2022-01-20 東亞合成株式会社 キャリアペプチドフラグメントおよびその利用
EP4188422A4 (en) * 2020-07-30 2024-08-28 University of Washington Transferrin receptor binding proteins
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
EP4298132A4 (en) * 2021-02-23 2025-03-12 Ichilov Tech Ltd. FUSION PROTEINS FOR THE TREATMENT OF CNS DISEASES
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023023031A2 (en) * 2021-08-17 2023-02-23 Blaze Bioscience, Inc. Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof
JPWO2023022234A1 (cg-RX-API-DMAC7.html) * 2021-08-19 2023-02-23
KR102934033B1 (ko) * 2021-10-01 2026-03-06 서울대학교산학협력단 혈액 뇌장벽 투과용 펩타이드 및 이의 용도
CN118139896A (zh) * 2021-10-15 2024-06-04 南通壹宸生物医药科技有限公司 一种双特异性结合分子
CN115160408B (zh) * 2022-06-29 2025-04-22 辽宁天增祥生物科技有限公司 降压肽或中国蛤蜊降压肽提取物及其应用
CN115925981B (zh) * 2022-08-18 2025-05-23 河南工业大学 一种特异性靶向革兰氏阴性菌的抗菌肽及其应用
TWI877887B (zh) * 2022-11-29 2025-03-21 法信諾生醫股份有限公司 轉運胜肽及其應用
TW202434613A (zh) * 2023-02-17 2024-09-01 日商肽夢想股份有限公司 人類運鐵蛋白受體結合肽
KR20260021596A (ko) 2023-04-05 2026-02-13 아이오니스 파마수티컬즈, 인코포레이티드 Pln 발현을 감소시키는 화합물 및 방법
WO2024238304A2 (en) * 2023-05-12 2024-11-21 University Of Washington Improved transferrin receptor binding proteins
AU2024329222A1 (en) * 2023-08-18 2026-02-12 Eli Lilly And Company Engineered transferrin receptor binding peptides as well as methods of making and using the same
CN119896743B (zh) * 2023-10-26 2025-09-26 华南理工大学 一种基质金属蛋白酶响应的多功能仿生铁蛋白纳米材料及其制备方法与应用
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025096245A1 (en) * 2023-11-02 2025-05-08 The Regents Of The University Of California Design rules for endosomal escape
CN120647772A (zh) * 2024-03-15 2025-09-16 迦进生物医药(上海)有限公司 特异性结合转铁蛋白受体的多肽及其应用
CN120459270B (zh) * 2025-05-16 2026-06-09 中国人民解放军海军军医大学 OpiCa1或其纳米脂质体在制备治疗和/或预防心肌纤维化相关疾病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236499A1 (en) * 2000-11-30 2002-06-11 Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
US20040157330A1 (en) * 2003-01-09 2004-08-12 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
WO2013123457A1 (en) * 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2013177062A2 (en) * 2012-05-21 2013-11-28 Genentech, Inc. Methods for improving safety of blood-brain barrier transport
CN103897033A (zh) * 2014-03-31 2014-07-02 中国药科大学 转铁蛋白受体TfR特异性结合肽及其应用
CA2967830A1 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
AU2016282334B2 (en) * 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
CA3033082A1 (en) * 2016-08-06 2018-02-15 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use

Also Published As

Publication number Publication date
AU2019398467A1 (en) 2021-06-24
CA3120466A1 (en) 2020-06-18
WO2020124032A1 (en) 2020-06-18
EP3893913B1 (en) 2025-03-26
US20220048961A1 (en) 2022-02-17
CN113329758A (zh) 2021-08-31
EP3893913A4 (en) 2022-09-14
EP3893913A1 (en) 2021-10-20
JP2022513798A (ja) 2022-02-09
JP2025038018A (ja) 2025-03-18
JP7664158B2 (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
IL320597A (en) Transferrin receptor-targeting conjugates and their uses
IL275547A (en) Antigen-binding proteins target co-antigens
ZA202001285B (en) Antigen-binding proteins targeting shared antigens
EP3893913A4 (en) TRANSFERRIN RECEPTOR TARGETED PEPTIDES
IL275298A (en) Mitochondria-targeted peptides
ZA201808458B (en) Dual transit peptides for targeting polypeptides
GB201911187D0 (en) Receptor
IL281224A (en) Peptide compounds
IL318744A (en) Cell-penetrating peptides
IL283803A (en) binds peptides
GB201700557D0 (en) Novel peptides
SG11202005653RA (en) Novel peptide
IL288412A (en) peptides
GB201918693D0 (en) Peptide
GB201713700D0 (en) Peptide conjugates
IL290019A (en) Peptides to regulate melanocytes
GB201719520D0 (en) Neuroprotectvie peptide
IL282030A (en) Antibodies to EPN1
GB201906982D0 (en) Peptides
GB201912632D0 (en) Peptide
GB201902850D0 (en) Antimicroial peptides
GB201807863D0 (en) Peptides
GB201814364D0 (en) Peptide vaccines
GB201814365D0 (en) Peptide vaccines
GB201814367D0 (en) Peptide Vaccines